February 25, 2021
A new partnership between public and private sector institutions aims to advance the adoption of personalised healthcare in Singapore; part of this includes precision oncology for personalised cancer care.
Listen to Associate Professor David Tan, Senior Consultant from the National University Cancer Institute, Singapore speaking with Health Matters with Daniel Martin on CNA938. on what it takes to set up personalized healthcare and how a clinico-genomic database (CGDB) is going to impact cancer care in the future.
Singapore Translational Cancer Consortium (STCC) has signed its first cross-border partnership with the Australian Victorian Cancer Biobank (VCB) to foster collaborations in translational oncology research. As part of the partnership agreement, STCC and VCB will share its oncology specimen databases, allowing researchers to access a wider array of tissue samples for cancer research. Both organisations will also share tissue banking best practices, and establish outreach programmes to advance clinical research collaborations between the two countries.
SINGAPORE - The development of mRNA-based cancer vaccines in Singapore is being funded by the Ministry of Health (MOH), as part of its support for “competitive cancer research projects” here, said Senior Minister of State for Health Janil Puthucheary.
SINGAPORE – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd).